910 Companies

Access all companies

Find technology partners quickly.

Spotfolio tracks over one million companies in technology industries.

There are 910 companies in the field of Biopharma on spotfolio that produce or deliver products, that utilize or research technologies or that are otherwise engaged in topics such as Clinical, Drug, Biotech, Therapeutic, Research, Pharmaceutical, Scientific, Patients .

Start-ups (168)

Early-stage companies (259)

Established companies (417)

The majority of these companies is located in the following countries.

United States (447)

United Kingdom (70)

China (41)

Canada (40)

Example Companies

Find companies in your area

Nuance Biotech

early-stage

Access

  • Technologies
  • Core data such as location, employees, revenues
  • Similar and peer companies
  • and more

Web Quotes

200 million unique users a month, and a co-founder and Chairman of Nuance Biotech. more - Mark G Lotter CEO and Co-Founder Mark is an industry veteran having ...

Boehringer Ingelheim for 4 years and most recently BMS before joining Nuance Biotech. more - Abraham van Wyk Head Medical and Clinical Development South Africa ...

sealant (Human) FIBINGLURAAS more - Treanda more COMPANY NUANCE BIOTECH INC Nuance Biotech (Shanghai) Co. Ltd was founded in 2014. Nuance focuses on China's ...

by C-Bridge Capital to commercialize high-value pharmaceutical Nuance Biotech, a China-based specialty pharmaceutical company, today announced Series ...

Director of C-Bridge Capita - 06-20 2018 Pacira Pharmaceuticals and Nuance Biotech Announce License Agreement for EXPAREL® in China PARSIPPANY, N.J. and SHANGHAI ...

(GLOBE NEWSWIRE) -- Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX) and Nuance Biotech Co. Ltd (Nuance) today announced that they have entered into an agreement

Cinfa Biotech

early-stage

Access

  • Technologies
  • Core data such as location, employees, revenues
  • Similar and peer companies
  • and more

Web Quotes

Mundipharma wins 1st ever PLG deal of the year award for acquisition of Cinfa Biotech Win recognises the significance of the deal in enabling Mundipharma to ...

for malignancy (with the exception of chronic ...continue reading Cinfa Biotech receives positive CHMP opinion for Pelmeg® (pegfilgrastim), a proposed biosimilar ...

Neulasta® Munich, Germany, 21 September 2018 – The biosimilar company Cinfa Biotech today announced that the European Medicines Agency’s (EMA) Committee for ...

positive opinion recommending marketing auth...continue reading Cinfa Biotech begins US partnering and prepares US development for B12019, a proposed ...

to Neulasta® (pegfilgrastim) Pamplona, Spain, 14 December 2017 – Cinfa Biotech S.L., the biosimilars company of Cinfa Group, today announced the start ...

reading Cinfa Biotech presents additional clinical data for pegfilgrastim biosimilar candidate B12019 at the 59th ASH Annual Meeting Cinfa Biotech starts US

Cinfa Biotech begins US partnering and prepares US development for B12019, a proposed biosimilar to Neulasta® (pegfilgrastim) Pamplona, Spain, 14 December ...

December 2017 – Cinfa Biotech S.L., the biosimilars company of Cinfa Group, today announced the start of US partnering and the preparation of US development ...

participate in the Biotech Showcase® conference, taking place on January 8-10, 2018 in San Francisco, USA. During this event, Cinfa Biotech will meet with ...

the US market,” said Dr. Ruediger Jankowsky, Managing Director of Cinfa Biotech GmbH. “In parallel, we are preparing interactions with the FDA to agree ...

data package required for FDA approval of B12019.” About Cinfa Biotech Cinfa Biotech is headquartered in Pamplona, Spain, with offices in Munich, Germany ...

information, please visit: Contact: For Business Development: Cinfa Biotech S.L. Cinfa Biotech S.L. Travesía de Roncesvalles, 1 Dr. Dieter Braun E-31699 Olloki

ERA Biotech

established

Access

  • Technologies
  • Core data such as location, employees, revenues
  • Similar and peer companies
  • and more

Web Quotes

SOLUTIONS Zera Intein Protein Solutions, ZIP Solutions, is a Barcelona based biotech company dedicated to the discovery, development, and commercialization of ...

of innovative protein technologies for the pharmaceutical and biotech markets. Our two proprietary technologies, ZERA and SPLITTERA, are powerful tools ...

commercial products. She is a scientific co-founder of the company ERA Biotech. Since inception, she has been managing scientific projects, moving gradually ...

to become the Managing Director of ERA Biotech in January 2013. In February 2015 ZIP Solutions acquired ERA Biotech, and Dr. Bastida is since then Managing

founded in 2015, with the acquisition of the assets of the company ERA Biotech. Since 2018, the company is part of ADL BIONATUR SOLUTIONS, a group that ...

services for human and animal health. ADL BIONATUR SOLUTIONS is a global biotech corporate group comprising four companies, ADL Biopharma, Bionaturis, Biobide ...

complementary strengths have allowed the group to become a major player in biotech and pharmaceutical industries, both in terms of quality and innovation.

InterAx Biotech InterAx Biotech AG

start-up

Access

  • Technologies
  • Core data such as location, employees, revenues
  • Similar and peer companies
  • and more

Web Quotes

APR 2020 A Spanish-Swiss Liaison to fight COVID-19 APR 2020 InterAx Biotech supporting the COVID-19 initiative SARS-CoV-2/ACE-2 pseudovirus entry blocking ...

2020 A Spanish-Swiss Liaison to fight COVID-19 Read APR 2020 InterAx Biotech supporting the COVID-19 initiative SARS-CoV-2/ACE-2 pseudovirus entry blocking ...

blocking assay Read 2019 Expand Collapse DEC 2019 InterAx Biotech and GPCR Therapeutics Inc collaborate for the identification of compounds with superior ...

integration of machine learning into the InterAx… Read AUG 2019 InterAx Biotech and Boehringer Ingelheim collaborate for enabling the in-depth characterization ...

The EU has granted 4M euro to Martine Smit and… Read APR 2019 InterAx Biotech and Lundbeck A/S entered an agreement to enable the in-depth characterization ...

drug candidates using the proprietary InterAx… Read FEB 2019 InterAx Biotech received the Seal of Excellence by the European Commission February 2019

InterAx Biotech AG November 2020 InterAx Biotech AG, 4. November 2020 Confidential 1 InterAx is accelerating drug discovery Pharma R&D Productivity ...

GPCRs • 80% of known GPCRs are not yet targeted by an approved drug InterAx Biotech AG, 4. November 2020 Sources: Nature; Drug Discovery & Development 2 ...

Artificial Intelligence • Result: Improved prediction of drug action InterAx Biotech AG, 4. November 2020 3 AI assisted systems biology for advancing GPCR ...

desired in vivo effects InterAx Biotech AG, 4. November 2020 4 InterAx approach to drug candidate selection GPCR InterAx Biotech AG, 4. November 2020 Target ...

Dynamic assays GPCR Target Systems Biology “Hit or miss search” InterAx Biotech AG, 4. November 2020 Signaling fingerprint 6 InterAx approach to drug ...

fingerprint 2. Determination of signaling fingerprints 3. Clustering InterAx Biotech AG, 4. November 2020 4. ”Model guided selection” 7 Systems biology driven

Sagetis Biotech

established

Access

  • Technologies
  • Core data such as location, employees, revenues
  • Similar and peer companies
  • and more

Web Quotes

- HOME - TECHNOLOGY - NEWS & EVENTS - CONTACT - More SAGETIS BIOTECH GRANTS EXCLUSIVE LICENSE OF ITS VIROSHIELD TECHNOLOGY TO ARATINGA.BIO TNP FOR ...

AND PLASMID-BASED APPLICATIONS March 29, 2019 Sagetis Biotech March 29th, 2019 — Sagetis Biotech, S.L., today announced that it granted an exclusive license ...

applications in any therapeutic area. The relationship between Sagetis Biotech and aratinga.bio TNP builds upon earlier work conducted by aratinga.bio ...

Collaboration Research and Option Agreement established in 2017. Sagetis Biotech will keep providing aratinga.bio TNP its support and know-how in polymer ...

developments and treat serious human diseases". About Sagetis Biotech Sagetis Biotech is devoted to developing an innovative polymeric technology (Viroshield) ...

Sagetis Biotech is also developing SAG-101: a polymer-coated adenovirus for the treatment of pancreatic ductal adenocarcinoma. Sagetis Biotech has in-licensed

SAGETIS BIOTECH TO EVALUATE THE COATING OF AAVS FOR THE TREATMENT OF DUCHENNE MUSCULAR DYSTROPHY April 12, 2019 Sagetis Biotech Sagetis Biotech today ...

Project España has awarded Dr. Salvador Borrós and his team at Sagetis Biotech a one year extension to the signed grant to evaluate the coating of adeno-associated ...

The ongoing experiments with Adeno-associated vir... Read More SAGETIS BIOTECH GRANTS EXCLUSIVE LICENSE OF ITS VIROSHIELD TECHNOLOGY TO ARATINGA.BIO TNP ...

AND PLASMID-BASED APPLICATIONS March 29, 2019 Sagetis Biotech March 29th, 2019 — Sagetis Biotech, S.L., today announced that it granted an exclusive license ...

Boston - 4th - 6th Dec 2018 December 3, 2018 Sagetis Biotech Barcelona, Dec 3, 2018 - Sagetis Biotech is pleased to announce that Sagetis’ Chief Executive ...

Applications Receives US FDA Approval for Lutathera® February 2, 2018 Sagetis Biotech The approval represents one further step in the uphill battle against pancreatic

Use detailed technology terms.

Only spotfolio allows for searching with detailed technology terms, as we provide you with all topics that technology companies talk about.

Companies addressing these topics might be of specific interest to you, as they share more specific, niche topics.

Use Cases

Register now

Why Technology Scouting?

Technology scouting is the basis for your innovation management, identifies new technological developments as early as possible and protects you from disruptive business models.

Identify technology partners

Boost your market research

Look beyond major players

Build long and short lists

Collect technology leaders, providers, start ups and potential new partners in lists via simple tagging to take further steps with your team.